CRMD vs. IBRX, ARWR, HCM, EWTX, MIRM, AMRX, KYMR, GMTX, PTGX, and MESO
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include ImmunityBio (IBRX), Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), Edgewise Therapeutics (EWTX), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), Kymera Therapeutics (KYMR), Gemini Therapeutics (GMTX), Protagonist Therapeutics (PTGX), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry.
CorMedix vs.
ImmunityBio (NASDAQ:IBRX) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.
ImmunityBio has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.
ImmunityBio currently has a consensus target price of $13.58, suggesting a potential upside of 279.95%. CorMedix has a consensus target price of $15.67, suggesting a potential upside of 48.64%. Given ImmunityBio's higher probable upside, analysts clearly believe ImmunityBio is more favorable than CorMedix.
8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 83.4% of ImmunityBio shares are owned by insiders. Comparatively, 5.2% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, ImmunityBio had 7 more articles in the media than CorMedix. MarketBeat recorded 8 mentions for ImmunityBio and 1 mentions for CorMedix. ImmunityBio's average media sentiment score of 0.20 beat CorMedix's score of 0.00 indicating that ImmunityBio is being referred to more favorably in the media.
CorMedix has lower revenue, but higher earnings than ImmunityBio. CorMedix is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
CorMedix has a net margin of 0.00% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat CorMedix's return on equity.
CorMedix received 14 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 75.76% of users gave CorMedix an outperform vote while only 34.38% of users gave ImmunityBio an outperform vote.
Summary
CorMedix beats ImmunityBio on 10 of the 18 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
This page (NASDAQ:CRMD) was last updated on 2/21/2025 by MarketBeat.com Staff
Free CRMD Stock Alerts